Oncomed Pharmaceuticals Inc Revenue Growth Rates (OMED), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Oncomed Pharmaceuticals Inc  (OMED)
 

OMED's Revenue Growth by Quarter and Year

Oncomed Pharmaceuticals Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OMED Revenue (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
4th Quarter December 10.18
3rd Quarter September 19.52
2nd Quarter June 6.87
1st Quarter March 7.85
FY 44.42

OMEDs Annual Revenue
Oncomed Pharmaceuticals Inc's Revenue in the fiscal year 2018 $ 44.42 millions
Oncomed Pharmaceuticals Inc's Revenue in the fiscal year 2017 $ 38.15 millions
Oncomed Pharmaceuticals Inc's Revenue in the fiscal year 2016 $ 25.15 millions
Oncomed Pharmaceuticals Inc's Revenue in the fiscal year 2015 $ 25.90 millions
Oncomed Pharmaceuticals Inc's Revenue in the fiscal year 2014 $ 39.56 millions




OMED Revenue fourth quarter 2018 Y/Y Growth Comment
Oncomed Pharmaceuticals Inc reported drop in Revenue in the fourth quarter 2018 by -50.66% to $ 10.18 millions, from the same quarter in 2017.
The fall in the fourth quarter 2018 Oncomed Pharmaceuticals Inc's Revenue compares unfavorably to the Company's average Revenue rise of 35.59%.

Looking into fourth quarter 2018 results within Major Pharmaceutical Preparations industry 202 other companies have achieved higher Revenue growth. While Oncomed Pharmaceuticals Inc' s Revenue meltdown of -50.66% ranks overall at the positon no. 4009 in the fourth quarter 2018.


OMED Revenue ( Y/Y Growth %) 2018
 2017 2016 2015
4th Quarter December -50.66 % 231.83 % -9.06 % -19.62 %
3rd Quarter September 282 % -13.68 % 26.23 % -75.34 %
2nd Quarter June 10.81 % -7.05 % 42.22 % -22.09 %
1st Quarter March 26.41 % -2.2 % -34.47 % 60.96 %
FY   16.42 % 51.67 % -2.89 % -

Financial Statements
Oncomed Pharmaceuticals Inc's fourth quarter 2018 Revenue $ 10.18 millions OMED's Income Statement
Oncomed Pharmaceuticals Inc's fourth quarter 2017 Revenue $ 20.64 millions Quarterly OMED's Income Statement


OMED Revenue (Quarter on Quarter Growth %)

 2018
 2017 2016 2015
4th Quarter December -47.83 % 303.91 % 5.07 % 45.84 %
3rd Quarter September 184.13 % -17.58 % -11.24 % 0 %
2nd Quarter June -12.48 % -0.16 % 5.04 % -51.6 %
1st Quarter March -61.97 % -0.16 % -7.16 % 13.87 %
FY (Year on Year)   16.42 % 51.67 % -2.89 % -


Back to OMED Growth rate Comparisons >> Back to OMED Growth rate Comparisons >>


Revenue fourth quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #203
Healthcare Sector #494
Overall #4009

Revenue Y/Y Growth Statistics
High Average Low
282.26 % 35.59 % -75.35 %
(Sep 30 2018)   (Sep 30 2015)
Revenue fourth quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #203
Healthcare Sector #494
Overall #4009
Revenue Y/Y Growth Statistics
High Average Low
282.26 % 35.59 % -75.35 %
(Sep 30 2018)   (Sep 30 2015)

Revenue by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Oncomed Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
341.06 % 42.94 % -61.97 %
(Sep 30 2013)  


OMED's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2018 Oncomed Pharmaceuticals Inc disclosed fall in Revenue from the third quarter by -47.83% to $ 10.18 millions, from $ 19.52 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2018 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 220 other companies have achieved higher Revenue quarter on quarter growth. While Oncomed Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 3750.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #221
Healthcare Sector #514
Overall #3750
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #221
Healthcare Sector #514
Overall #3750
Revenue Q/Q Growth Statistics
High Average Low
341.06 % 42.94 % -61.97 %
(Sep 30 2013)  


OMED's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2018 Oncomed Pharmaceuticals Inc disclosed fall in Revenue from the third quarter by -47.83% to $ 10.18 millions, from $ 19.52 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2018 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 220 other companies have achieved higher Revenue quarter on quarter growth. While Oncomed Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 3750.


Oncomed Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2018)		 12 Months Ending
(Sep 30 2018)		 12 Months Ending
(Jun 30 2018)		 12 Months Ending
(Mar 31 2018)		 12 Months Ending
(Dec 31 2017)
Cumulative Revenue 12 Months Ending $ 44.42 $ 54.88 $ 40.47 $ 39.79 $ 38.15
Y / Y Revenue Growth (TTM) 16.43 % 131.23 % 64.85 % 59.06 % 51.69 %
Year on Year Revenue Growth Overall Ranking # 453 # 188 # 0 # 239 # 179
Seqeuential Revenue Change (TTM) -19.05 % 35.62 % 1.7 % 4.29 % 60.76 %
Seq. Revenue Growth (TTM) Overall Ranking # 398 # 142 # 0 # 1199 # 505


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2018 period, Oncomed Pharmaceuticals Inc's cumulative twelve months Revenue were $ 44 millions, company would post below average annual Revenue growth of 60.76% year on year, if the fiscal year would end at Dec 31 2018.
A slow-down in the Oncomed Pharmaceuticals Inc's Revenue growth from the 19.52% growth in Sep 30 2018.

In the Healthcare sector 108 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 188 to 453.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 54
Healthcare Sector # 109
Overall # 453

Revenue TTM Y/Y Growth Statistics
High Average Low
141.58 %
 23.06 %
-48.85 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 98
S&P 500 # 398
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2018 period, Oncomed Pharmaceuticals Inc's cumulative twelve months Revenue were $ 44 millions, company would post below average annual Revenue growth of -48.85% year on year, if the fiscal year would end at Dec 31 2018.
A slow-down in the Oncomed Pharmaceuticals Inc's Revenue growth from the 19.52% growth in Sep 30 2018.

In the Healthcare sector 108 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 188 to 453.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 54
Healthcare Sector # 109
Overall # 453

Revenue TTM Y/Y Growth Statistics
High Average Low
141.58 %
23.06 %
-48.85 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 98
S&P 500 # 398




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OMED's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Dec 31 2018 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2018
Zimmer Biomet Holdings Inc -0.16%$ -0.159 millions
Tg Therapeutics Inc -0.25%$ -0.249 millions
Hanger inc.-0.31%$ -0.309 millions
Surgalign Holdings Inc -0.55%$ -0.546 millions
3m Company-0.56%$ -0.563 millions
Bio rad Laboratories Inc -0.72%$ -0.717 millions
Quest Diagnostics Inc-1.39%$ -1.394 millions
Biomarin Pharmaceutical Inc-1.42%$ -1.421 millions
Inspiremd Inc -1.44%$ -1.439 millions
Star Equity Holdings Inc -1.46%$ -1.459 millions
Prophase Labs Inc -1.47%$ -1.470 millions
Meridian Bioscience Inc -1.54%$ -1.536 millions
Sonida Senior Living Inc -1.60%$ -1.601 millions
Hca Healthcare Inc -1.78%$ -1.784 millions
Immune Design Corp.-1.86%$ -1.856 millions
Bausch Health Companies Inc -1.94%$ -1.942 millions
Opiant Pharmaceuticals Inc -2.21%$ -2.211 millions
Htg Molecular Diagnostics Inc-2.23%$ -2.227 millions
Invacare Holdings Corporation-2.31%$ -2.307 millions
Pediatrix Medical Group Inc -2.46%$ -2.458 millions
Gilead Sciences Inc -2.59%$ -2.589 millions
Dentsply Sirona Inc -2.87%$ -2.869 millions
Diversicare Healthcare Services Inc -3.26%$ -3.258 millions
Encision Inc -3.33%$ -3.326 millions
Orasure Technologies Inc-3.43%$ -3.425 millions
Alphatec Holdings Inc -3.58%$ -3.576 millions
Stereotaxis Inc -3.81%$ -3.806 millions
Sophiris Bio Inc.-3.85%$ -3.846 millions
Kaya Holdings Inc -4.21%$ -4.206 millions
Utah Medical Products Inc-4.36%$ -4.362 millions


About Oncomed Pharmaceuticals Inc Revenue Growth Rates (OMED), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.